Li Xipeng, Zhao Yu, Zhang Tao, Xing Da
MOE Key Laboratory of Laser Life Science & Institute of Laser Life Science, College of Biophotonics, South China Normal University, Guangzhou, 510631, P. R. China.
Guangdong Provincial Key Laboratory of Laser Life Science, College of Biophotonics, South China Normal University, Guangzhou, 510631, P. R. China.
Adv Healthc Mater. 2021 Feb;10(3):e2001240. doi: 10.1002/adhm.202001240. Epub 2020 Nov 25.
Mitochondria-targeted photodynamic therapy (Mt-PDT), which enables the photogenerated cytotoxic oxygen species with fatal oxidative damage to block mitochondrial functions, has been considered as a promising method to enhance the anticancer effectiveness. Aiming at the challenges of PDT, in the past few decades, numerous mitochondria-targeting molecular agents have been developed to boost the PDT efficacy via directly destroying the mitochondria or activating mitochondria-mediated cell death pathways. Herein, a review for recent advances of Mt-PDT is highlighted including: mitochondrial targeting design principles and strategies, therapeutic performance of mitochondria-targeted agents-mediated PDT as well as the agent-free Mt-PDT. In addition, it puts together the achievements of the combinatory mitochondria-anchoring PDT and other anticancer strategies, demonstrating the advantages provided by Mt-PDT. The existing challenges are discussed and future settlements for the development of mitochondria-specific agents are also forecasted.
线粒体靶向光动力疗法（Mt-PDT）可使光生细胞毒性氧物种造成致命的氧化损伤，从而阻断线粒体功能，被认为是一种增强抗癌效果的有前景的方法。针对光动力疗法面临的挑战，在过去几十年中，人们开发了许多线粒体靶向分子试剂，通过直接破坏线粒体或激活线粒体介导的细胞死亡途径来提高光动力疗法的疗效。本文重点综述了Mt-PDT的最新进展，包括：线粒体靶向设计原则和策略、线粒体靶向试剂介导的光动力疗法的治疗性能以及无试剂的Mt-PDT。此外，还汇总了联合线粒体锚定光动力疗法和其他抗癌策略的成果，展示了Mt-PDT的优势。讨论了现有挑战，并对线粒体特异性试剂的未来发展解决方案进行了预测。
